Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282

S. Chakrabarty, Y. J. Danels, B. H. Long, J. K. Willson, M. G. Brattain

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

BMY25282, a newly designed analogue of mitomycin C (MMC) with the substitution of an amidine group at position 7 of MMC, can circumvent MMC resistance in a series of human colonic carcinoma cells that were selected for resistance to MMC (J.K.V. Willson et al., Cancer Res., 45:5281-5286, 1985). In this study MMC resistance was found to be associated with an inability of the resistant cells to activate MMC. However, both the MMC-sensitive and -resistant cells were observed to metabolize BMY25282 extensively in vitro to a reactive species capable of alkylating 4-(p-nitrobenzyl)pyridine (a trapping agent for activated drug). The results of these studies suggested that the deficient cellular reductive activating mechanism was associated with MMC resistance and that analogue BMY25282 was able to overcome this deficiency in MMC-resistant cells by virtue of its enhanced activation.

Original languageEnglish (US)
Pages (from-to)3456-3458
Number of pages3
JournalCancer Research
Volume46
Issue number7
StatePublished - 1986
Externally publishedYes

Fingerprint

Mitomycin
Carcinoma
Amidines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chakrabarty, S., Danels, Y. J., Long, B. H., Willson, J. K., & Brattain, M. G. (1986). Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282. Cancer Research, 46(7), 3456-3458.

Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282. / Chakrabarty, S.; Danels, Y. J.; Long, B. H.; Willson, J. K.; Brattain, M. G.

In: Cancer Research, Vol. 46, No. 7, 1986, p. 3456-3458.

Research output: Contribution to journalArticle

Chakrabarty, S, Danels, YJ, Long, BH, Willson, JK & Brattain, MG 1986, 'Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282', Cancer Research, vol. 46, no. 7, pp. 3456-3458.
Chakrabarty, S. ; Danels, Y. J. ; Long, B. H. ; Willson, J. K. ; Brattain, M. G. / Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282. In: Cancer Research. 1986 ; Vol. 46, No. 7. pp. 3456-3458.
@article{068a2aa7f9174a758adcb53530cea8cb,
title = "Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282",
abstract = "BMY25282, a newly designed analogue of mitomycin C (MMC) with the substitution of an amidine group at position 7 of MMC, can circumvent MMC resistance in a series of human colonic carcinoma cells that were selected for resistance to MMC (J.K.V. Willson et al., Cancer Res., 45:5281-5286, 1985). In this study MMC resistance was found to be associated with an inability of the resistant cells to activate MMC. However, both the MMC-sensitive and -resistant cells were observed to metabolize BMY25282 extensively in vitro to a reactive species capable of alkylating 4-(p-nitrobenzyl)pyridine (a trapping agent for activated drug). The results of these studies suggested that the deficient cellular reductive activating mechanism was associated with MMC resistance and that analogue BMY25282 was able to overcome this deficiency in MMC-resistant cells by virtue of its enhanced activation.",
author = "S. Chakrabarty and Danels, {Y. J.} and Long, {B. H.} and Willson, {J. K.} and Brattain, {M. G.}",
year = "1986",
language = "English (US)",
volume = "46",
pages = "3456--3458",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282

AU - Chakrabarty, S.

AU - Danels, Y. J.

AU - Long, B. H.

AU - Willson, J. K.

AU - Brattain, M. G.

PY - 1986

Y1 - 1986

N2 - BMY25282, a newly designed analogue of mitomycin C (MMC) with the substitution of an amidine group at position 7 of MMC, can circumvent MMC resistance in a series of human colonic carcinoma cells that were selected for resistance to MMC (J.K.V. Willson et al., Cancer Res., 45:5281-5286, 1985). In this study MMC resistance was found to be associated with an inability of the resistant cells to activate MMC. However, both the MMC-sensitive and -resistant cells were observed to metabolize BMY25282 extensively in vitro to a reactive species capable of alkylating 4-(p-nitrobenzyl)pyridine (a trapping agent for activated drug). The results of these studies suggested that the deficient cellular reductive activating mechanism was associated with MMC resistance and that analogue BMY25282 was able to overcome this deficiency in MMC-resistant cells by virtue of its enhanced activation.

AB - BMY25282, a newly designed analogue of mitomycin C (MMC) with the substitution of an amidine group at position 7 of MMC, can circumvent MMC resistance in a series of human colonic carcinoma cells that were selected for resistance to MMC (J.K.V. Willson et al., Cancer Res., 45:5281-5286, 1985). In this study MMC resistance was found to be associated with an inability of the resistant cells to activate MMC. However, both the MMC-sensitive and -resistant cells were observed to metabolize BMY25282 extensively in vitro to a reactive species capable of alkylating 4-(p-nitrobenzyl)pyridine (a trapping agent for activated drug). The results of these studies suggested that the deficient cellular reductive activating mechanism was associated with MMC resistance and that analogue BMY25282 was able to overcome this deficiency in MMC-resistant cells by virtue of its enhanced activation.

UR - http://www.scopus.com/inward/record.url?scp=0022640856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022640856&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 3456

EP - 3458

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -